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e-mail address: drf15@hotmail.comAbdulrahman Samir Khairallah, MD ⇑AbstractA 29 year-old healthy Saudi female presented with a 1 week history of headache followed by decreased vision in both eyes.
Biomicroscopy revealed anterior uveitis without hypopyon, posterior synechia or keratic precipitate. Fundus examinations were
remarkable for serous retinal detachment and hyperemic discs. Fundus fluorescein angiogram showed a hot disc with multiple
pinpoint leakage in both eyes. CT scan and MRI were normal, all uveitis workups were negative.
Five months later, the patient presented with complete criteria of Vogt–Koyanagi–Harada disease including a 2 weeks history of
tinnitus, alopecia, poliosis and vitiligo. Headache alone followed by decreased vision before the onset of neurological and auditory
symptoms can be an initial presentation of VKH disease. VKH should be considered in the differential diagnosis of atypical pre-
sentation of symptoms.
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Vogt–Koyanagi–Harada disease (VKH) is a bilateral intra-
ocular inflammation usually associated with systemic manifes-
tations such as meningismus, dysacusis, poliosis, and
vitiligo.1–3 It is an autoimmune disease that targets melano-
cyte rich organs, such as the eye, inner ear, meninges, and
skin.4
For unknown reasons, there is a greater preponderance in,
females compared to males, in patients between the second
and fifth decades and in heavily pigmented races.1
The diagnostic criteria of VKH disease are categorised into
complete, incomplete and probable.5 Headache alone does
not fulfil the diagnostic criteria and is insufficient for the
diagnosis.
The Vogt–Koyanagi–Harada disease is clinically divided
into four phases, prodromal, acute uveitic, convalescent,
and chronic recurrent phase.1 The longer the duration ofthe disease, the greater the number of ocular complications
associated with worse visual outcomes.6
Here we report a case of patient with headache as an ini-
tial presentation of VKH disease with typical complete clinical
features manifesting later over the course of 1 year follow up.Case report
A 29 year old Saudi female not known to have any medical
illnesses presented with a 1 week history of headache fol-
lowed by decreased vision in both eyes. There was no history
of previous surgery or ocular trauma. There was no history of
tinnitus, weakness, alopecia, vitiligo, poliosis, vomiting, back
pain, numbness or joint pain. At presentation, visual acuity
was 20/50 and 20/100 in the right eye and left eye, respec-
tively. Anterior segment examination demonstrated +2 cells
in anterior chamber bilaterally. Both pupils had normale:
al.com
Figure 1. Bilateral multiple serous retinal detachment and disc hyperemia.
Figure 2. Early (A) and late (B) phase of fluorescein angiogram showing hot disc with multiple pinpoint hyperfluorescent area with leakage of dye in both
eyes.
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sion and the intraocular pressure in each eye were within nor-
mal limits. Fundus examination showed multiple serous
retinal detachments, deep yellow lesions consistent with cho-
roiditis and hyperemic disc in both eyes without vitritis
(Fig. 1).
Fundus fluorescein angiogram (FFA) showed hot disc with
the classic findings of multiple areas with pinpoint hyperfluo-
rescent spots at the level of retinal pigment epithelium with
leakage and pooling of dye in the subretinal space of bothFigure 3. Resolved serous retinal detachment and opticeyes (Fig. 2). Computed tomography (CT) scan and magnetic
resonance imagining (MRI) were normal. All appropriate uve-
itis investigations including tuberculin skin tests, antinuclear
antibody, angiotensin converting enzyme, venereal diseases
research laboratory, blood titre for toxoplasma, rubella, cyto-
megalovirus, and herpes were negative.
The patient was diagnosed as a probable case of VKH dis-
ease and started on topical prednisolone acetate 1% six
times a day and oral prednisone 80 mg/day for 1 week then
a weekly taper of 5 mg and cycloplegic agent (homatropinedisc hyperemia in both eyes, in comparison to Fig. 1.
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intraocular inflammation after 2 weeks of treatment and the
vision improved to 20/25 in each eye.
One month later, the patient was placed on tapering oral
steroid when she started to complain of numbness of fingers
and around the mouth. Magnetic resonance imaging (MRI) of
the brain with and without contrast was performed to rule out
multiple sclerosis. Both fundi showed normal retina and optic
discs with resolving serous retinal detachment and disc
hyperemia (Fig. 3).
Two months later, the patient elected to discontinue her
medications without consultation and presented with severe
anterior chamber reaction in both eyes and posterior syn-
echia in the right eye. Topical and systemic steroids were re-
sumed with cycloplegic agent.
Five months later, the patient presented with the com-
plete diagnostic criteria for Vogt–Koyanagi–Harada disease
including a 2 weeks history of tinnitus, alopecia, poliosis
and vitiligo. She could not tolerate the oral steroid anymore,Figure 4. Bilateral sun
Figure 5. After treatment (A) early and (B) late phase of fluorescein angiogra
Compare with Fig. 2.hence we prescribed systemic cyclosporine 75 mg/day and
the oral steroid was reduced to 25 mg/day.
At one year follow up, the patient was asymptomatic but
clinically she developed a sunset glow fundus bilaterally
(Fig. 4). The previous finding of hyperfluorescent areas and
leakage on fluorescein angiogram was resolved (Fig. 5).
The plan was to continue the oral cyclosporine and low
dose oral steroid for one more year to control the VKH
disease.Discussion
Our patient presented with rare and unusual initial find-
ings of VKH disease manifesting as headache only without
other features of meningisms (malaise, fever, nausea, abdom-
inal pain, stiffness of the neck and back or combination of
these factors) as described by revised diagnostic criteria of
VKH,5 followed by decreased vision bilaterally. Mostset glow fundus.
m showing bilateral resolving of hyperfluorescent area with no leakage.
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ical findings followed by decreased vision7 and headache
alone is insufficient for the diagnosis of VKH disease.
On the literature review to the best of my knowledge very
few cases had been reported with headache as an initial man-
ifestation of VKH disease (Cho et al.,7 Tavsanli et al.8 and Kos-
ma et al.9).
Although headache is a common symptom in VKH cases it
is not usually the only initial symptom and is most commonly
accompanied by disturbances in visual acuity. Beniz et al.10
studied 48 patients, most presented with an initial complaint
of diminished visual acuity, although 32 patients (67%) had
headache but it was not the initial presentation. Chee et al.11
reviewed 178 eyes of 89 patients, the most common present-
ing symptom was blurring of vision (98.88%) and it was
accompanied by headaches in 51.69% of patients. Tugal-Tut-
kun et al12 analysed 45 patients, and found headache was the
most frequent symptom which was present in 31 patients
(69%) but the decreased visual acuity also occurred at pre-
sentation. For example they found 0.1 visual acuity in 23 eyes
(60.5%), 0.1–0.5 visual acuity in ten eyes (26.3%), and better
than 0.5 in five eyes (13.2%).
Differing features of headache have been described in
VKH. For example, Kosma et al.9 described the headache
as continuous, diffuse and throbbing in nature, while Cho
et al.7 described it as a thunderclap headache which is differ-
ent from our patient as she had diffuse headache, moderate
in intensity without any other specific features of headache.
Early in the course of the disease our patient fulfilled the
criteria of probable VKH disease as she had bilateral ocular
involvement with no previous history of trauma or ocular sur-
gery, no evidence of other ocular disease, no neurological
(headache only is insufficient) and auditory findings. Five
months later patient fulfils the criteria of complete VKH dis-
ease as she developed auditory (tinnitus) and integumentary
findings (alopecia, poliosis and vitiligo).
The management for this condition is high dose systemic
corticosteroid early in the disease, which is associated with
decreased dermatological feature, ocular inflammation,
recurrence, and better visual outcome.13–15 Systemic cortico-
steroid in acute VKH disease whether oral therapy only or a
combination of intravenous and oral, do not appear to matter
significantly in terms of change in visual acuity or develop-
ment of visually significant complications.16
In conclusion headache alone followed by decreased vi-
sion before the onset of neurological and auditory symptoms
can be an initial presentation of VKH disease, which shouldbe considered in the differential diagnosis of atypical cases
of VKH disease.
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